Thyroid Cancer Diagnostics Market To Reach $5.03 Billion By 2033

Thyroid Cancer Diagnostics Market Growth & Trends 

The global thyroid cancer diagnostics market size is estimated to reach USD 5.03 billion by 2033, expanding at a CAGR of 5.86% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth of the market is attributed to increasing disease prevalence and the emergence of novel diagnostic products. Although cancer is uncommon worldwide, the incidence rate is on the rise-driven by more sensitive and precise tools to diagnose the disease. It develops as a result of abnormal cell division in the thyroid gland. Since the glandular hormones regulate several functions, such as weight, body temperature, heart rate, and blood pressure, structural or functional anomalies are likely to affect several or all of the aforementioned factors.

Growing awareness and public health initiatives encourage more individuals, especially those at higher risk, to seek screening. This, combined with expanding healthcare infrastructure and increased healthcare spending worldwide, facilitates greater access to advanced diagnostic services. Regulatory support and ongoing research efforts are fostering the introduction of innovative diagnostic solutions, including liquid biopsies and artificial intelligence-driven imaging analysis.

The market has undergone a paradigm shift over the last few years, driven by the introduction of biomarkers and the launch of improved diagnostic products. However, disease progression and recurrence remain high, especially among older patients. Strong unmet needs present a key opportunity to develop breakthrough, first-in-class diagnostics of the disease.

 Request a free sample copy or view report summary: Thyroid Cancer Diagnostics Market Report

Thyroid Cancer Diagnostics Market Report Highlights

• Papillary carcinoma led the cancer type segment with the largest revenue share of 80. 03% in 2024. This is attributed to heightened public awareness, the expansion of screening initiatives, and significant progress in imaging and molecular diagnostic methods, all of which have made it possible to identify cases earlier and with greater accuracy.

• Follicular carcinoma diagnostics is expected to grow at a CAGR of 5.6% over the forecast period, owing to an increased vulnerability among women, a stronger emphasis on prompt diagnosis, and ongoing advancements in diagnostic technologies.

• Imaging technique held the largest revenue share, 36.92%, in 2024, driven by the incorporation of enhanced imaging resolution and artificial intelligence for precise tumor localization and monitoring.

• Biopsy technique is expected to grow at a significant CAGR over the forecast period, owing to advances in biomarker analysis and next-generation sequencing, which have improved diagnostic accuracy and supported individualized care.

• The hospital laboratories segment led the market with the largest revenue share of 37.44% in 2024.

• North America dominated the thyroid cancer diagnostics market with the largest revenue share of 40.17% in 2024, primarily driven by the presence of advanced healthcare infrastructure, ongoing awareness campaigns, and access to innovative diagnostic solutions.

Thyroid Cancer Diagnostics Market Segmentation

Grand View Research has segmented the global thyroid cancer diagnostics market based on cancer type, technique, end use, and region:

Thyroid Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)

• Papillary carcinoma

• Follicular carcinoma

• Others

Thyroid Cancer Diagnostics Technique Outlook (Revenue, USD Million, 2021 - 2033)

• Blood Test

• Imaging

• Biopsy

• Others

Thyroid Cancer Diagnostics End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Hospital Laboratories

• Cancer Diagnostic Centers

• Research Institutes

• Others

Thyroid Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • Spain

  • France

  • Italy

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Thyroid Cancer Diagnostics Market

• Abbott

• F.Hoffmann-La Roche Ltd.

• Thermo Fisher Scientific, Inc.

• Siemens Healthcare GmbH

• Bio-Rad Laboratories, Inc

• GE HealthCare

• Hologic, Inc.

• Koninklijke Philips N.V.

• Toshiba Corporation

• Agilent Technologies, Inc.

• Illumina, Inc.